Medical technology company Stryker has launched Surpass Evolve Flow Diverter in the US, following its approval by the Food and Drug Administration (FDA).
Considered to be the first 64-wire cobalt-chromium flow diverter in the US, the Surpass Evolve is developed to redirect blood flow and encourage aneurysm healing.
An aneurysm is caused by the weakening of a blood vessel part, which makes the vessel bulge and fill with blood. While brain aneurysms are considered life-threatening, aneurysms can occur in any blood vessel in the body.
The increased braid angle of the Surpass Evolve offers improved flow diversion and a flexible implant for better vessel wall contact.
Additionally, the higher mesh density of the device enables faster aneurysm occlusion for patients, the company noted.
Stryker Neurovascular division president Mark Paul said: “Surpass Evolve is our fourth PMA approval and second flow diverter approved by the FDA in the last two years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“It augments our robust hemorrhagic portfolio and reflects our ongoing commitment to invest in technologies that will drive improved patient outcomes. Stryker is dedicated to working with our customers to bring life-saving technologies to patients suffering from brain aneurysms.”
Surpass Evolve was launched in Europe last year and is currently approved in more than 45 countries.
Physicians in these countries have confirmed the device as easier-to-use than its predecessor, the company added.
In May last year, Stryker obtained FDA premarket approval for its Neuroform Atlas Stent System for the treatment of brain aneurysms.
The company entered a definitive agreement last year to acquire 100% of the issued and outstanding shares of Wright Medical Group for $30.75 per share.